Back to top
more

Insulet Corporation (PODD)

(Delayed Data from NSDQ)

$273.74 USD

273.74
172,199

+1.23 (0.45%)

Updated Jul 29, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (172 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insulet Corporation [PODD]

Reports for Purchase

Showing records 141 - 160 ( 249 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 141

09/24/2015

Daily Note

Pages: 6

Neulasta On Body Injector Symphony Health Sales Estimate

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 142

08/20/2015

Daily Note

Pages: 5

July Neulasta Sales Suggest Impressive OBI Adoption Representing 22% of Neulasta Franchise; Positive for PODD Drug Delivery; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 143

08/20/2015

Daily Note

Pages: 5

July Neulasta Sales Suggest Impressive OBI Adoption Representing 22% of Neulasta Franchise; Positive for PODD Drug Delivery; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 144

08/13/2015

Company Report

Pages: 9

Despite Some Confusion, The Message That Things Are Improving Is Clear; Raising PT to $40; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 145

07/30/2015

Daily Note

Pages: 5

2Q Beat And Favorable Guidance Suggest PODD Is Regaining Momentum; Historical Accounting Issue Is A Minor Distraction; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 146

07/30/2015

Daily Note

Pages: 5

Amgen Highlights Solid Launch of Neulasta On- Body Injector (OmniPod inside)

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 147

07/30/2015

Daily Note

Pages: 5

2Q Beat And Favorable Guidance Suggest PODD Is Regaining Momentum

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 148

07/30/2015

Daily Note

Pages: 5

Amgen Highlights Solid Launch of Neulasta On- Body Injector (OmniPod inside)

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 149

07/22/2015

Daily Note

Pages: 4

June Estimate Suggests On-Body Injector Represents 10% of Neulasta Sales; Positive for PODD''s Drug Delivery Business Outlook

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 150

07/22/2015

Daily Note

Pages: 4

June Estimate Suggests On-Body Injector Represents 10% of Neulasta Sales; Positive for PODD''s Drug Delivery Business Outlook

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 151

07/17/2015

Daily Note

Pages: 41

Medical Devices - 2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15

Provider: Wedbush Securities Inc.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 152

07/17/2015

Daily Note

Pages: 41

2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15 Remains Positive

Provider: Wedbush Securities Inc.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 153

07/14/2015

Industry Report

Pages: 6

Medical Devices - Takeaways from J-J''s 2Q15 Results

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 154

06/28/2015

Company Report

Pages: 9

Positive OmniPod Reimbursement Developments; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 155

06/11/2015

Daily Note

Pages: 5

FDA Warning Letter Highlights Past Quality Issues; No Impact Expected to the Business

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 156

06/11/2015

Daily Note

Pages: 5

FDA Warning Letter Highlights Past Quality Issues; No Impact Expected to the Business

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 157

05/01/2015

Company Report

Pages: 6

Stability in US OmniPod More Than Offset by Shortfalls Elsewhere; Lowering PT to $36; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 158

04/22/2015

Company Report

Pages: 6

Amgen Partnership Off to a Strong Start

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 159

04/16/2015

Daily Note

Pages: 40

1Q15 Preview: Trends Look Better Than Initially Expected

Provider: Wedbush Securities Inc.

Price: 75.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 160

04/14/2015

Industry Report

Pages: 18

Proprietary Survey of Diabetes Educators Positive for Insulet and Tandem; Raising PT of PODD to $38

Provider: Wedbush Securities Inc.

Price: 50.00

Research Provided by a Third Party